Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

@article{Lower2013ArmodafinilFS,
  title={Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.},
  author={Elyse E Lower and Atul Malhotra and Victoria Surdulescu and Robert P. Baughman},
  journal={Journal of pain and symptom management},
  year={2013},
  volume={45 2},
  pages={
          159-69
        }
}
CONTEXT Fatigue has been identified in more than one-half of patients with sarcoidosis. Although fatigue is not synonymous with impaired quality of life, most studies of sarcoidosis identify fatigue as a major cause of impaired quality of life. OBJECTIVES To test the hypothesis that stimulants may have a role in the treatment of fatigued sarcoidosis patients, even without objective evidence of daytime sleepiness. METHODS This was a double-blind, placebo-controlled, crossover study of… Expand
Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol
TLDR
The primary objective is to collect data determining the feasibility of a future study powered to determine the clinical efficacy of methylphenidate for sarcoidosis-associated fatigue, and the trial is presently open and will continue until July 2018. Expand
Managing fatigue in sarcoidosis – A systematic review of the evidence
TLDR
There is evidence to support a treatment effect of anti-tumour necrosis factor (TNF)-αtherapies and neurostimulants in patients with organ-threatening disease, but trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation. Expand
Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids.
TLDR
Both fatigue as well as HRQL improved significantly, and largely parallelly, with treatment for sarcoidosis, and correlated with clinical recovery and change in health-related quality of life (HRQL). Expand
The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review
TLDR
A systematic review of the literature suggests a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory. Expand
Armodafinil for fatigue associated with menopause: an open-label trial
TLDR
Preliminary results suggest a therapeutic effect of armodafinil on fatigue affecting quality of life during menopause, and a potential benefit for other menopsause-related symptoms. Expand
Repository corticotropin for Chronic Pulmonary Sarcoidosis
TLDR
Repository corticotropin treatment was prednisone-sparing and associated with significant improvement in DLCO, PET scan, and patient-reported outcome measures, and a dose of 40- unit RCI twice a week was as effective as 80-unit RCI and was better tolerated. Expand
Sarcoidosis-associated fatigue: an often forgotten symptom
  • S. Kapoor
  • Medicine
  • Expert review of clinical immunology
  • 2013
TLDR
The importance of sarcoidosisassociated fatigue and the need to increase awareness about it among physicians, especially pulmonologists are clearly illustrated. Expand
Improvement of lupus-associated fatigue with modafinil: Report of two cases
TLDR
It is demonstrated, for the first time, that modafinil (MODA) treatment is a potential pharmacological treatment option in selected patients with LAF. Expand
Nonorgan manifestations of sarcoidosis.
TLDR
Fatigue, small fiber neuropathy (SFN) and neuropsychological symptoms are highlighted andMultidisciplinary programs that include physical therapy, patient education and psychological support were found to improve fatigue and mood disorders. Expand
Neuropsychobiological Fingerprints of Chronic Fatigue in Sarcoidosis
TLDR
Inadequate adjustment of brain activation with increasing demands appears to be a potential neurobiological marker of chronic fatigue in sarcoidosis patients, and the angular gyrus was the major area in which fatigue patients showed smaller increase in brain activation compared to those without fatigue. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
TLDR
Treatment with d-MPH was associated with a significant improvement in sarcoidosis-associated fatigue and was well tolerated. Expand
Fatigue in sarcoidosis: a systematic review
TLDR
The need for longitudinal prospective studies to better define sarcoidosis fatigue is emphasized, to explore its impact on quality of life, define aggravating or alleviating factors and evaluate new potential treatment strategies. Expand
Modafinil for the Treatment of Multiple Sclerosis-Related Fatigue
TLDR
Modafinil is a reasonable therapeutic option in this patient population, although larger, long-term, randomized controlled studies are necessary to further elucidate the appropriate dose of modaf inil, its effects on MS-related fatigue, and adverse effects associated with its use. Expand
Using Modafinil to Treat Fatigue in Parkinson Disease: A Double-Blind, Placebo-Controlled Pilot Study
TLDR
It was demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms and there was no difference between groups over time for any dimension of the MFI. Expand
Modafinil treatment of fatigue in patients with ALS: A placebo‐controlled study
TLDR
Modafinil may be a promising intervention for fatigue in ALS patients and Replication in a larger study is needed. Expand
Modafinil in treatment of fatigue in multiple sclerosis
TLDR
Treatment with modafinil significantly improves fatigue and sleepiness and is well tolerated by patients with MS, unlike the higher dose regimen required in narcolepsy. Expand
Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
TLDR
Data suggest that 200 mg/day modafinil significantly improves fatigue and is well tolerated in patients with MS. Expand
Modafinil for fatigue in MS
TLDR
There was no improvement of fatigue in patients with multiple sclerosis treated with modafinil vs placebo according to the Modified Fatigue Impact Scale. Expand
A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.
TLDR
In this pilot study modafinil was well-tolerated and effective for fatigue in patients with cancer, and improvements were also seen in mood, quality of life, and functional status. Expand
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
TLDR
Modafinil rapidly improved fatigue and daytime wakefulness, with significantly greater mean improvements from baseline than placebo in fatigue (FSS) scores at week 2 and sleepiness (ESS) Scores at week 1; the differences between modaf inil and placebo at week 6 were not statistically significant. Expand
...
1
2
3
4
5
...